Body Acne Positivity for Summer 2025
This was just one of the many ways Kihal's body breakouts began to impact her life, both IRL and online. 'I'd spend two hours editing one Instagram photo just trying to blur every little bump,' she says. 'I was terrified of what people would say if they saw my real skin.' Though everyone's guilty of being their own worst critic every once in a while, unfortunately, the unwanted comments about her skin weren't just in her head. 'People did make comments,' she explains. 'Little jokes that stuck with me for years,' she adds. 'It completely messed with my mental health.'
By the time Kihal was diagnosed with Sharp's Syndrome—an autoimmune disease that made her breakouts worse—she felt invisible and deeply alone. So, in 2019, she started posting about her acne journey on Instagram. The response? Overwhelming. 'I realized so many people were going through the same thing. We just didn't see it anywhere.'
She's not wrong: According to the American Academy of Dermatology, acne affects around 40 to 50 million Americans, and approximately half have facial and body acne. According to Kunal Malik, MD, FAAD, a board-certified dermatologist, body acne is caused by the same factors as facial acne—think oil, clogged pores, bacteria, and inflammation. 'But body skin is thicker and the follicles are deeper, especially on the back and chest, which means breakouts can be more painful and harder to treat,' he says. Throw in friction from tight clothing, sitting for long periods, and sweating through heat waves, and it's a perfect storm.
Summer, unsurprisingly, turns up the risk for breakouts, heat rashes, and irritation. 'Heat and humidity increase oil production and sweat, which creates ideal conditions for acne-causing bacteria,' Dr. Malik explains. 'And when sweat isn't washed off quickly—like after a concert or beach day—clogged pores follow.' And just like chronic breakouts on your face, Dr. Malik notes that body acne can be hereditary.
Textured skin anywhere on your body is totally normal and common, but you'd never know it from your FYP or literally any festival-headlining pop star stripped down to their skivvies. Every visible body looks airbrushed into oblivion—so where's the buttne and chest breakouts? What about the KP, ingrowns, or hyperpigmentation?
Well, it of course still exists. It's just being covered up. While facial acne has become somewhat of an accessory that can be dolled up with kitschy pimple patches, but body acne has yet to get that treatment. 'Natural' makeup looks with hints of skin texture peeking through have become the norm, but those walking the red carpet in a low-cut gown or gearing for a photo shoot still get a full glam routine, just for their chest and back.
Celebrity makeup artist Neil Scibelli even has an arsenal of products specifically for covering up bodne (along with varicose veins, tattoos, you name it) for his pre–red carpet clients. 'I'll use a green color corrector for redness, then a matte, transfer-proof concealer, and finish with powder and setting spray to lock everything in,' he explains. 'I'll typically cover veins, tattoos, scars, or hyperpigmentation with a peach or orange color corrector and then add foundation over that.'
It's no big surprise that celebrities get every inch of their bodies primed and prepped before a big moment in front of cameras. But with filters and AI-supported editing apps added to the mix, real and curated images are becoming hard to distinguish. Social media's obsession with perfection isn't doing any favors for our collective mental health and self-esteem, including when it comes to our skin. 'Social media is still a highlight reel,' says Jessica Stern, PhD, licensed clinical psychologist and clinical assistant professor of NYU Langone Health's Department of Psychiatry. 'The more curated the image, the more people compare—and the worse they feel.'
For Kihal, the impact of that shame was deeply personal. 'I started believing my skin had to be perfect to be worthy of being seen,' she says. 'It took years to unlearn that, and honestly, I'm still working on it.'
She's far from alone. Acne—whether on the face or body—has been linked to increased depression, anxiety, and, in severe cases among adolescents, suicidal ideation. A 2011 study found that people with moderate to severe acne were significantly less likely to pursue romantic relationships.
'Shame thrives on isolation,' says Dr. Stern. 'The less something is discussed, the more it makes someone feel isolated, alone, or defective.' Because body acne is not commonly discussed in the media, Dr. Stern explains this lack of representation can falsely portray as if it is less prevalent, 'which then can make someone who has it feel like there is something wrong with them, which can lead to self-criticism, low confidence, self-rejection, and a poor sense of self.'
However, thanks to the rise of skin-positive creators like Kihal, a much-needed shift is slowly happening. Her followers send messages every day thanking her for helping them feel seen. 'Especially when I show my bacne or scars—things people are still scared to share—I get DMs saying, 'I've never seen someone with skin like mine before.' That's the whole point,' she says.
But as much as social media has helped normalize real skin, it's also part of the problem. 'There's so much pressure to keep up an image,' Kihal says. 'We see 'authentic' posts that are still filtered. Celebs and influencers rarely admit to editing. If more people were honest about what's real and what's touched up, it would change everything.'
Some brands are finally breaking the smooth-skin illusion. A few campaigns in recent years from brands like Billie, Starface, and Fur have showcased stretch marks, acne scars, and texture in an authentic, human way. Still, most beauty marketing treats body texture of any kind like a 'before' problem. Not something that's just there sometimes or that people can live with and feel good about.
So what needs to happen? We simply need to accept ourselves, bumps and all, regardless of what we see on TikTok. 'If you catch yourself thinking, Everyone's judging me, ask: So what? What would happen if you stopped hiding?' says Dr. Stern.
Kihal echoes her advice. 'For a long time, I thought I had to shrink myself to be accepted,' she says. 'Now, I know better. If I want to wear a backless dress, I will. If I want to go to the beach, I'll go. I'm not waiting for my skin to be 'perfect' anymore.'
Jennifer is the former beauty editor for BestProducts.com, where she's testing out everything from the latest lip gloss to the craziest skincare trend sweeping the online beauty-verse. Her work has been featured in Allure, Byrdie, HelloGiggles, and more. When she's not swatching eyeshadow all over her arms, you can find the NYC-based editor scouring for hours on end for vintage finds, eating pad thai, and hanging out with her cat, Chunks.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
2 hours ago
- Newsweek
Potato Salad Recall Map Shows New Warning Issued in 5 States
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Hans Kissle is recalling its Red Potato Bliss Salad due to an undeclared wheat allergen discovered in a labeling error. Newsweek reached out to the company for comment via phone on Tuesday night and left a voicemail. Why It Matters Numerous recalls have been initiated this year due to the potential of damaged products, foodborne illness, contamination and undeclared food allergens. Millions of Americans experience food sensitivities or allergies every year. According to the U.S. Food and Drug Administration (FDA), the nine "major" food allergens in the U.S. are eggs, milk, fish, wheat, soybeans, Crustacean shellfish, sesame, tree nuts and peanuts. People with a wheat allergy could experience a "serious or life-threatening allergic reaction if they consume these products," the FDA warns. What To Know In the alert, the FDA says that 66 units of the potato salad are being recalled because of the mislabeling issue. The product is packaged in a 16-ounce container that is clear and has a white lid. The product's UPC Code number is 036217673706 and has a use-by date of August 20, 2025. The container says, "Hans Kissle Tri Color Twist Pasta Salad" while the top says, "Hans Kissle Red Bliss Potato Salad," the FDA says. There have been no reported illnesses or adverse reactions as it relates to this recall as of Tuesday, the FDA says. The recalled potato salads were distributed to Stop & Shop retail locations in five states, the alert notes. Below is a map showing the affected states, which include New York, New Jersey, Rhode Island, Connecticut and Massachusetts. What People Are Saying The FDA in the alert, in part: "The recall was initiated after it was discovered that 66 containers of Tricolor Twist Pasta Salad were mislabeled with the incorrect top label. While the front label correctly identifies the product, the top label misrepresents it as Red Bliss Potato Salad. The actual product contains wheat, which is not declared on the top label." In an email to Newsweek in January, the FDA said: "Most recalls in the U.S. are carried out voluntarily by the product manufacturer and when a company issues a public warning, typically via news release, to inform the public of a voluntary product recall, the FDA shares that release on our website as a public service. The FDA's role during a voluntary, firm-initiated, recall is to review the recall strategy, evaluate the health hazard presented by the product, monitor the recall, and as appropriate alert the public and other companies in the supply chain about the recall." It added: "The FDA provides public access to information on recalls by posting a listing of recalls according to their classification in the FDA Enforcement Report, including the specific action taken by the recalling company. The FDA Enforcement Report is designed to provide a public listing of products in the marketplace that are being recalled." Additional information on recalls can be found via the FDA's Recalls, Market Withdrawals, & Safety Alerts. What Happens Next Consumers are advised to return the recalled product to the original place of purchase for a full refund, the FDA says. People with additional questions may contact the company via phone at 978-556-4500 from 8 a.m. to 5 p.m. ET weekdays.
CNBC
7 hours ago
- CNBC
Healthy Returns: Medicare, Medicaid will reportedly pilot covering obesity drugs – a potential win for drugmakers
For once, the Trump administration may be giving some drugmakers a reason to celebrate. The Trump administration is planning to experiment with covering costly weight loss drugs under Medicare and Medicaid, the Washington Post reported on Friday. That plan could expand access to millions of Americans with obesity who can't currently afford Novo Nordisk's Wegovy and Eli Lilly's Zepbound, blockbuster GLP-1 drugs that cost around $1,000 per month before insurance. In a statement to CNBC about the plan, the Department of Health and Human Services said all drug coverages undergo a "cost-benefit review." The Centers for Medicare and Medicaid Services "does not comment on potential models or coverage," the department added. The reported plan – if it ultimately takes effect – would be a huge win for Eli Lilly, Novo Nordisk and many Americans. Spotty insurance coverage of obesity drugs remains the biggest barrier to access for patients – and it's choking broader uptake and revenue growth for the two pharmaceutical giants. Many health plans, including Medicare, cover GLP-1s for treatment of diabetes, but not obesity. Medicaid coverage of obesity drugs is limited and varies by state, according to health policy research organization KFF. But it's important to remember that this plan isn't exactly new. In November, the Biden administration proposed having Medicare and Medicaid cover obesity treatments, which would have extended access to roughly 3.4 million Medicare beneficiaries and about 4 million Medicaid recipients. The proposal was controversial at the time, as it would cost taxpayers as much as $35 billion over the next decade, a congressional analysis found. The Trump administration dropped that proposal in April, but said it could reconsider coverage of those drugs in the future. Let's get into what the newest reported iteration of the plan looks like. Under the Trump administration's reported pilot plan, state Medicaid programs and Medicare Part D plans would be able to voluntarily choose to cover Ozempic, Wegovy, Mounjaro and Zepbound for patients for "weight management" purposes. That's according to several Centers for Medicare and Medicaid Services documents obtained by the Post. The plan is expected to start in April 2026 for Medicaid and January 2027 for Medicare plans, the Post reported. It's unclear how exactly the plan will play out, Jared Holz, Mizuho health care equity strategist, said in a note to clients on Friday. Holz said he expects the government to put some coverage parameters in place related to factors like age, body weight, body mass index and other comorbidities, or coexisting chronic health conditions. He also said the pricing of the drugs will be a "major consideration." Holz said he expects the government to pay less than the current list prices of drugs. But having that coverage would expand access and could help drive higher sales volumes, he noted. Another factor to consider is how much the government is willing to crack down on so-called compounding pharmacies, which are allowed in rare cases to sell cheaper, unapproved versions of GLP-1s. The pharmaceutical industry fiercely opposes those knock-off GLP-1s, as their safety and efficacy aren't vetted by regulators and they are, in some cases, illegally sold at scale. Holz said the industry's complaints to the government about compounded GLP-1s have so far "not been met with a widespread shut-down." But overall, Holz said the Trump administration's reported willingness to consider covering obesity drugs is "a slight positive as far as industry sentiment." It's definitely a breath of fresh air for Eli Lilly, Novo Nordisk and other drugmakers – including Amgen, Roche, AstraZeneca and Pfizer – that are hoping to bring their own obesity drugs to market. The last six months have been anything but smooth for the broader industry: The Trump administration has ratcheted up calls for drugmakers to lower U.S. drug prices, overhauled federal health agencies and could impose sweeping tariffs on pharmaceuticals imported into the country any day now. We'll keep watching to see whether this plan gets implemented, so stay tuned for our coverage! Feel free to send any tips, suggestions, story ideas and data to Annika at After reporting its second straight earnings miss and guidance cut, UnitedHealth Group completed its executive sweep by replacing CFO John Rex. Executives on the earnings call admitted to mis-execution in Medicare Advantage and pledged to get back to profitability and win back investor trust. Nearly two years ago it was CVS Health under pressure, after profits in the company's Aetna health insurance division were torpedoed by low Medicare Advantage Star quality ratings. This week, CVS beat and raised its outlook on the strength of its MA program. CEO David Joyner, now one year into the job, told me he feels good about the turnaround at Aetna and its Medicare business. On top of that, the company saw market share gains in its stores, thanks in part to winning over Rite Aid customers. Humana, similarly, has seen progress on its turnaround, but CFO Celeste Mellet told me that all insurers are grappling with pricing plans for next year amid high medical costs. One big cost driver right now, Mellet told CNBC, is oncology drugs, as some expensive therapies are now being used in combination. The next moment of truth for the Medicare Advantage players will come over the next six weeks – when they'll learn the fate of their Star ratings for 2026 plans. Long-time health-care executive Dr. Marc Harrison has stepped down as CEO of General Catalyst's Health Assurance Transformation Company, or HATCo, and has moved into a strategic advisor role, CNBC has confirmed. The venture capital firm brought in Harrison and announced the formation of HATCo in 2023. In a release at the time, General Catalyst said the company would work closely with health system partners, and that it would eventually acquire and operate its own health system. Months later, HATCo announced its plans to buy Summa Health, a nonprofit integrated health system in northeast Ohio. Under its new structure, Summa would become a for-profit organization, and General Catalyst said it would introduce new tech-enabled solutions that aim to make care more accessible and affordable. Buying a health system is an unprecedented move in the venture industry, and the deal wasn't well received by some members of the Ohio community. Hundreds signed a petition urging Summa to remain a nonprofit and to halt negotiations with HATCo. Ohio Attorney General Dave Yost conditionally approved the deal in June, though he outlined a number of "enforceable commitments" as part of the agreement. HATCo will have to notify the Attorney General of transactions that could trigger antitrust concerns for 10 years after the deal closes, for instance. Harrison went to medical school in the late 1980s and has spent most of his career within health systems, most recently as CEO of Intermountain Healthcare. General Catalyst told CNBC that Harrison will continue to provide the firm's CEO, Hemant Taneja, with clinical insights and will remain connected to its ecosystem in his new role. "It became increasingly clear to both Marc and to us that Marc's role would best be accomplished as a strategic advisor to Hemant Taneja as we bring that ambition and vision to life," a General Catalyst spokesperson said. Daryl Tol, the head of General Catalyst's Health Assurance Ecosystem, was promoted to president of HATCo, the spokesperson said. He will spearhead the firm's day-to-day- work with Summa Health leadership. General Catalyst has also appointed Kate Walsh, the former Massachusetts Secretary of Health and Human Services, to HATCo's board. In addition, she will serve as the chair of the board at Summa Health once the transaction closes. "We are grateful for Marc's leadership and collaboration as co-founder and CEO to help get us to this point in the evolution of HATCo, and we look forward to leveraging his invaluable perspective as we continue to progress," the spokesperson said.
NBC News
7 hours ago
- NBC News
It's a real grind to meet matcha demand these days
Your midday matcha latte is getting more expensive and harder to come by as supply shortages and skyrocketing demand squeeze cafés. Matcha, the bright green powder swirled into drinks, ice cream and pastries, has soared in popularity over the last few years, fueled by social media and a post-pandemic tourism boom in Japan. But Japan's supply is drying up with record heat and a shortage of tea farmers, spiking prices that could rise even more with new 15% tariffs on Japanese imports into the United States. Tea experts say true matcha is only grown and produced in Japan. The shortage has made it harder for cafés to get matcha. 'Normally when we order our powder, it should take about one month to two months,' said Alfred Chan, manager and co-founder of Urban Matcha, a Las Vegas café that opened in 2023. 'But right now it takes over about six months to get to us.' Matcha comes from the tea plant, Camellia sinensis. The plant was brought from China to Japan around 750 CE, according to Rebecca Corbett, a professor of Japanese studies at the University of Southern California. But, she said, matcha itself wasn't made in Japan until around 1250 CE and eventually came to only be produced there. Matcha making is a specialized art: A traditional cup involves grinding shade-grown tea leaves into a fine powder, then mixing that powder into hot water with a bamboo whisk. The drink is used in Japanese tea ceremonies and appreciated for its apparent health benefits, with some evidence that matcha could help lower blood pressure, reduce inflammation and improve concentration. 'People do like the health benefits of matcha, and that's not new,' Corbett said. 'In the 1200, 1300s, people in Japan were talking about that and promoting drinking matcha as a cure for hangovers, for example.' Now, matcha's a global sensation, with customers waiting in long lines at cafés to get their hands on a cup. 'I get matcha all the time,' said Emma Willingham, a customer at Matcha Cafe Maiko in New York City. 'Every time someone else is getting coffee, I'm like, 'OK, give me the matcha.'' Tea experts say social media helped fuel the matcha craze, with people posting their colorful creations. 'If you look on Instagram and TikTok, the bright green color of matcha, it's very visually appealing,' Corbett said. 'And there's also the cool Japan factor, the sort of aesthetics of trendy minimalism. It's all being packaged around matcha.' Tourism in Japan has climbed over the last few years, with a record-breaking 36.9 million people visiting in 2024, according to the Japan National Tourism Organization and the Japan Tourism Agency. Some of those travelers have returned home with bags full of matcha. The demand has gotten so high that some Japanese companies have begun to limit the amount of matcha people can buy. It's not just high demand parching the industry — it's also limited supply. The number of tea farmers has dropped dramatically over the past couple decades: Between 2000 and 2020, 4 out of every 5 tea producers or farmers stopped making tea, according to the Global Japanese Tea Association. 'There's not a lot of people to care for the fields,' said Lauren Purvis, president and CEO of Mizuba Tea Co., which works with Japanese producers to sell matcha and other teas online and to coffee shops. 'As the farmers get older, there'd be tea fields being abandoned.' Record heat also hurt this spring's harvest in Japan. Purvis said some farmers are reporting their harvest was down 20% to 30% from last year due to heat. 'Just a couple years ago, we were really worried about Japanese tea existing, and now everybody wants it,' Purvis said. 'We were just dealing with abandoned fields, and now Japan can't make enough.' It's not easy to scale up production: Only a tiny fraction of Japan's land can be farmed, and experts say making matcha is time-consuming. Purvis said some farmers are working to convert their fields to make more tencha, the leaves used to make matcha, but that takes time. Right now, the supply of matcha is not enough to quench global thirst as matcha companies like Purvis' Mizuba Tea say they're running out. 'We got our 1,000 units in, and it's just like, poof, they're out the door,' Purvis said. Kettl, a company selling Japanese teas online and in its New York and Los Angeles cafés, has had record sales as matcha flies off the shelves. 'We have seen extreme demand,' Zach Mangan, founder of Kettl, said. 'Recently 200 tins went up, and they were gone in about 16 hours.' Shops like Kettl are spending more than ever on some of their matcha options. Mangan said most of Kettl's suppliers doubled their prices from last year — and the company has had to pass some of those added costs on to consumers. He is worried Kettl will need to raise prices even more with the new 15% tariffs on Japanese goods. 'If it were just 15%, and the shortage wasn't causing the demand and the increase in prices, we might be able to just say, 'Whatever, we'll take care of it,'' Mangan said. 'But it makes it more complicated when you're factoring both the tariffs and the increase in raw material costs in Japan.' U.S. consumers are already shelling out more for their matcha lattes. The lattes are averaging $6.15 a cup, according to payment processing company Square, up from $5.84 last year. While U.S. consumers are pulling back on spending at major food chains like McDonald's, Chipotle and Wendy's, they are pouring more money into beverages. Sales at U.S. beverage chains are forecast to grow by 4.5% this year, according to food research company Technomic. 'You have this sort of little bit of barbell effect of super cheap, no bells and whistles, and then go all-out on that one-time experience instead of maybe a continuous type of spend,' said Ming-Tai Huh, head of food and beverage at Square. Even as matcha prices rise, he expects consumers will keep buying it. 'It's a flavor that's both attractive in color, in flavor, in health,' Huh said, 'and those are just good recipes for a long-standing success.'
